
ACOG Stock Forecast & Price Target
ACOG Analyst Ratings
Bulls say
Alpha Cognition is well-positioned for success in the biopharmaceutical industry as they have a clear differentiating factor in their drug ZUNVEYL, which has shown lower incidence of GI-related side effects and insomnia, as well as potential impact on behavioral symptoms of Alzheimer's disease. The company also has a potential market expansion opportunity with their sublingual ODT formulation and a strong financial position with a recent settlement agreement and new director appointment. Furthermore, they have reported strong revenue and a net loss beat for the first quarter, with a positive outlook for future revenue growth and sufficient cash on hand to fund operations until cash flow break-even.
Bears say
Alpha Cognition is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases like Alzheimer's. Despite the company's current efforts to commercialize and market its lead product ZUNVEYL, there are several concerns that could impact its success, including slow market uptake, pricing pressures, and potential setbacks in clinical trials. Overall, the company faces significant risks and may struggle to achieve profitability in the near term.
This aggregate rating is based on analysts' research of Alpha Cognition Inc and is not a guaranteed prediction by Public.com or investment advice.
ACOG Analyst Forecast & Price Prediction
Start investing in ACOG
Order type
Buy in
Order amount
Est. shares
0 shares